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The enzymatic activity of CD73 produces immune-suppressing adenosine. In CD73 deficient hosts, tumor growth and
tumor infiltration by Tregs and type 2 immunosuppressive macrophages is reduced. Pharmacological inhibition of CD73
in wild-type mice has similar tumor-suppressing effects. Host CD73 on leukocytes and endothelial cells is thus
detrimental for the anti-tumor immunity.
CD73/ecto-5'-nucleotidase is a cell-surface
protein expressed on a subset of leukocytes,
including CD4
+CD25
+FoxP3
+ Tregs, vas-
cular and lymphatic endothelial cells and
certain epithelial cells.
1 It is an ecto-
enzyme, which dephosphorylates extra-
cellular AMP into adenosine (Fig.1).
2-4
This reaction is an integral part of the
adenosinergic signaling pathway that
encompasses the following sequential
hydrolyzing reactions: ATP   ADP  
AMP   adenosine   inosine. ATP and
ADP generally give rise to pro-inflamma-
tory signals via purinergic P2X and P2Y
receptors. Adenosine, in contrast, binds
to adenosine receptors and evokes anti-
inflammatory responses. The enzymatic
activity of CD73 is involved in the
regulation of leukocyte extravasation, vas-
cular barrier function, and immunosup-
pressive functions of Tregs, which are all
relevant to tumor immunity.
CD73 can also be expressed on certain
cancer cell types.
5,6 These include leuke-
mia, glioblastoma, melanoma, ovarian,
gastric, colon and breast cancer. In these
cells CD73 activity confers increased
migratory and invasive capacity and aug-
ments neovascularization of the tumors.
Inhibition of cancer cell CD73 activity can
impair tumor progression.
The potential role of host CD73 in
tumor growth has not been addressed.
In our study, we used CD73-negative
tumor cells (B16 melanomas) and CD73-
deficient mice to dissect the contribution
of host CD73 to the tumor progression
and anti-tumor immunity.
7
Although themajority of both CD4
+ and
CD8
+ T-cells in the lymph nodes normally
express CD73, the absence of CD73 did
not alter their numbers.
7 Nevertheless,
the extracellular adenosinergic signaling
cascade of T-lymphocytes was abnormal
in CD73-deficient mice. CD73-negative
T-cells showed much higher ATPase and
ADPase activities, and practically no ecto-
5'-nucleotidase activity when compared
with the wild-type controls. Thus, since
the ATP and ADP hydrolyzing activities
are increased, and the dephosphorylation
of AMP into adenosine is reduced in
the CD73-deficient mice, the net effect
appears to be the accumulation of AMP.
The growth of primary subcutaneous
tumors from CD73-negative melanoma
cells, and their metastases to the draining
lymph nodes were attenuated in CD73-
deficient hosts.
7 Since CD73 is normally
expressed both on the endothelium and on
leukocytes, we next studied which of these
cell types would be relevant for the altered
anti-tumor responses.
Since adenosine is proangiogenic, the
CD73 deficiency might result in an ineffi-
cient angiogenic switch in tumors. We
found that CD73 is indeed induced in
a subpopulation of neoangiogenic vessels
within the melanomas.
7 However, there
was no difference in the numbers of blood
or lymphatic neovessels within the tumors
when comparing CD73-deficient and
wild-type mice. Nevertheless, binding of
isolated wild-type tumor-infiltrating leuko-
cytes to CD73-deficient tumor vasculature
was impaired by ~50% when compared
with the binding to the wild-type CD73
expressing tumor vasculature in in vitro
adhesion assays. Thus, CD73 appears not
to be necessary for the formation of tumor
neovessels, but is expressed on those, and
may contribute to the leukocyte immigra-
tion into the tumors (Fig.1).
The lack of CD73 might also alter
immune-suppressing functions of tumor
infiltrating leukocytes. To study this alter-
native, we enumerated different leukocyte
subtypes from the tumors. We did not
observe any genotype-specific differences in
the overall numbers of intratumoral CD4
+
T-helper cells, CD8
+ T-cytotoxic cells
or F4/80
+ macrophages.
7 However, the
tumors grown in CD73-deficient hosts
had significantly fewer FoxP3
+ lymphocytes
and macrophage mannose receptor-positive
(type 2) macrophages in the tumors. More-
over, in microarray analyses the tumor
infiltrating leukocytes in the CD73-
deficient mice had more IFNc and NOS2
mRNA (both markers of type 1 polarized
macrophages) than the wild-type controls.
Together these data suggest that the
intratumoral accumulation of immune
suppressive cell types, Tregs and type 2
macrophages, is compromised in the
absence of host CD73 (Fig.1).
Adenosinergic signaling can be mani-
pulated pharmacologically in vivo. Apyrase
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hydrolyzes ATP and ADP into AMP,
and AMPCP, a non-hydrolyzable nucleo-
tide analog, inhibits CD73 activity. We
observed that peritumoral injections of
either apyrase or AMPCP significantly
retarded melanoma progression and
inhibited accumulation of immune-
suppressing cell types in wild-type mice.
7
The same drugs had no effect on tumor
growth in CD73-deficient hosts. Thus,
pharmacological lowering of peritumoral
ATP levels or adenosine production phe-
notypically reproduced the effects seen in
gene deletion experiments.
Recently, these findings have been
recapitulated by two independent groups.
8,9
They show that ablation of host CD73
suppresses the growth of several tumor
cells types in vivo. At least in OVA-
expressing model tumors, lack of host
CD73 results in increased accumulation
of antigen-specific, IFNc producing
CD8
+ T cells in the tumors. In Tregs
CD73 was shown to be functionally
important for their mune-suppressing
functions in tumors. Moreover, the
endothelial CD73 was involved in the
recruitment of both anti-tumor leukocytes
and blood-borne metastatic melanoma cells
also in vivo.
Thus, the emerging concept is that
CD73 on both host and tumor cell side is
involved in tumor progression (Fig.1).
Tumor cell CD73 enhances the migratory
properties of malignant cells and con-
tributes to the immuno-evasion. On the
host leukocytes, CD73 activity also
contributes to the immunosuppression.
On normal and neoangiogenic vessels,
CD73 regulates the influx of leukocytes.
Inhibition of CD73, which is induced
under hypoxic conditions in tumors, by
enzyme inhibitors, siRNA or function
blocking monoclonal antibodies results
in attenuated tumor progression. There-
fore, ectoenzymatic modulation of cancer
may offer attractive therapeutic options in
future.
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Figure1. The CD73 on hematopoetic and non-hematopotic cells of the host regulates anti-tumor immunity. The enzymatic activity CD73 is depicted at the
top. The involvement of endothelial and leukocyte CD73 in leukocyte extravasation and immune suppression in wild-type and CD73-deficient mice are
illustrated. CD73 regulates recruitment of both CD73-positive and -negative leukocytes by modulating the endothelial adhesion molecules and permeability,
and CD73 may also have direct adhesive functions. Immune suppression is mainly mediated throughthe production of adenosine. In addition, certain cancer
types express CD73, and it augments the migration of these malignant cells and further renders the tumor microenvironment more immune-suppressing.
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